Cardiovascular Pathology – a Factor of the Adverse Course of Diabetic Polyneuropathy


Hennadii Chupryna
Viktoriia Dubynetska
Kateryna Kachur


Diabetic polyneuropathy (DP) and angiopathy are interdependent processes, as disturbances in the microcirculatory system of peripheral nerves lead to increased axonal damage and is a kind of predictor of polyneuropathy progressing [6]. 80% of deaths from diabetes mellitus (DM) are associated with cardiovascular catastrophes, including coronary heart disease (CHD), stroke and peripheral artery disease [3].

The objective: to analyze the most common cardiovascular pathology (CVP) and show its impact on the course of DP in type I and II DM.

Materials and methods. Was clinically examined 101 patient with DP. The examined patients were divided into groups: with DP on the background of type 1 DM (group I) (n=54) and with DP on the background of type II DM (group II) (n=47), and also were divided into subgroups: DP on the background of type I and II DM and existing CVP (including diabetic angiopathy) 82 (82%) (subgroup А) and with the DP on the background of DM type I and II without CVP – 19 (19%) (subgroup В). Patients were examined to determine the neurological status, were performed laboratory and instrumental methods of examination. Static calculation was performed in MS Excel 2003 and in the programme STATISTICA 10.

Results. Regarding to the patients of subgroup А and В we noted the natural predominance of trophic disorders, changes in the reflex sphere and sensitivity in subgroup А. Patients of group II more often than in group I had pathology of the cardiovascular system. Hypertension (HT) and CHD in both cases were registered with a high frequency. In subgroup А there was a combination of several nosologies: from the respiratory, urinary, gastroenterological system (1%), urinary and gastroenterological (3%), gastroenterological and endocrine (2%), urinary and endocrine (1%). In subgroup В diseases of urinary and gastroenterological pathology were found in (5%), gastroenterological (5%), endocrine (11%). The examined patients from group I and with the concomitant CVP have lower linear velocity of blood flow (LVBF) on both tibial arteries, patients in group II – have marginally higher LVBF. Analysis of the results of duplex scanning of lower extremity arteries showed a high incidence of stenosis, in particular the anterior tibial arteries (ATA) up to 30–40%, posterior tibial arteries (PTA) up to 40–50% and occlusion (PTA and femoral, popliteal, tibial segment) in individuals of group I.

Conclusions. In patients with DP on the background of type I and II DM and available CVP (subgroup А), the clinical manifestations of polyneuropathy were quite pronounced, especially in the field of trophic disorders, because CVP enhances the ischemia of the microsaceous channel of the peripheral nerves. In addition, persons with concomitant CVP have a wide range of another comorbid pathology, which accelerates the onset of DM complications.


How to Cite
Chupryna, H., Dubynetska, V., & Kachur, K. (2021). Cardiovascular Pathology – a Factor of the Adverse Course of Diabetic Polyneuropathy. Family Medicine, (2-3), 28–33.
Topical issues
Author Biographies

Hennadii Chupryna, P. L. Shupyk National Medical Academy of Postgraduate Education

Hennadii M. Chupryna,

Department of Neurology and Reflexotherapy

Viktoriia Dubynetska, P. L. Shupyk National Medical Academy of Postgraduate Education

Viktoriia M. Dubynetska

Kateryna Kachur, Communal Enterprise « Rivne Regional Clinical Medical and Diagnostic Centre named after V. Polishchuk» of Rivne Region Council

Kateryna A. Kachur


Abbott A. et al. Prevalence and Characteristics of Painful Diabetic Neuropathy in a Large Community-Based Diabetic Population in the U.K. Diabetes Care, 2011, Oct. 34(10):2220-4.

Ang L., Jaiswal M., Martin C. & Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr. Diab. Rep. 14, 528(2014).

Beckman JA, Creager MA, Libby P. Diabetes and athero sclerosis: epidemiology, pathophysiology and management. JAMA. 2002;287:2570–81.

Boulton A, Knight G, Drury J & Ward JD. The prevalence of symptomatic, diabetic neuropathy in an insulin-treated population. Diabetes Care, 1985;8:125-8.

Chupryna GM, Dubynetska VM, Vashenyuk OL, Vashenyuk NO. Features of clinical and paraclinic parameters and comorbidity in patients with diabetic polyneuropathy. Health of Society, 2019;8(5):174-8.

Dubynetska VM., Chupryna GM. Diabetic polyneuropathy: а look at the problem through the prism of comorbidity. East European Jornal of Neurology, 2019;1(25):36-46.

Dyck PJ et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology, 1993;43:817-24.

Franklin GM, Kahn LB, Baxter J, Marshall JA & Hamman RF. Sensory neuropathy in non-insulindependent diabetes mellitus. The San Luis Valley Diabetes study. Am. J. Epidemiol; 1990;131:633-43.

Janka HU, Standl E. Hyperinsulinaemia as a possible risk factor of macrovascular disease in diabetes mellitus. An overview. Diabete Metab, 1987 Jul;13(3Pt 2):279-83.

Kaminskyi AV, Kovalenko AN. Diabetes mellitus and obesity: a clinical guide to diagnosis and treatment. K.: Lira; 2010. 256 р.

Martin CL, Albers JW & Pop-Busui R. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care; 2014;37:31-8.

Mota M, Vasile A, Mitroy N. Risk Factors Leading to Amputation in Patients with Diabetes Mellitus. Maria Mota, Andriana Vasile, Nikoletta Mitroy and others. International Journal of Endocrinology; 2005;01:9-24.

Partanen J. et al. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N. Engl. J. Med; 1995:333,89-94.

Pop-Busui R. et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care; 2017; 40:136-54.

Pop-Busui R et al. Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Diabetes Care;2013:36:3208-15.

Stout RW. Hormones and Atherosclerosis: M.: Medicine, 1985:240.

Tesfaye S, Andrew JM, Boulton, Peter J Dyck, Roy Freeman et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. Diabetes Care. 2010 Oct; 33(10):2285-93.

Tesfaye S et al. Vascular risk factors and diabetic neuropathy. N. Engl. J. Med.; 2005:352, 341-50.

Tracy JA et al. The Spectrum of Diabetic Neuropathies. Physical Medicine and Rehabilitation Clinics N Am. 2008 Feb;19(1):1-26.1-v.